The elevated BcrAbl levels in clone A and B might have mediated their competitive advantage in the in vivo setting as suggested by earlier observations that BcrAbl expression increases with progression of CML from chronic phase to blast crisis [40, 45]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.